… pretreatment resistance to EGFR tyrosine kinase inhibitors. … the role of EGFR mutations in
the development of EGFR-related … this second mutation might be present in some tumors at a …

… In summary, our analysis revealed that EGFR mutant tumors have differing responses to
ICIs and underlying molecular profiles. These data serve as a foundation for further …

… that for advanced NSCLC patients with EGFR mutant tumors, initial therapy with a TKI … is
predictive of response to gefitinib, which suggests that EGFR mutation could be more common …

… Our results may help to explain the phenomenon of mixed tumor responses to EGFR TKIs
and provide a foundation for future diagnostic and therapeutic approaches to TKI resistance. …

… , in aggregate, identify drug responses in 40–80% of EGFR mutant cases. Our results differ
from a recent publication in which only 16% of EGFR mutant tumors were found to respond to …

… EGFR mutation pattern of 79 cases of NSCLC harboring EGFR mutations and compiled the
genotype-response … Other EGFR mutations and tumors with multiple EGFR mutations have …

… For patients whose tumors exhibit EGFR mutations, the response rate to gefitinib and … EGFR
mutations and the pivotal role they have in the sensitivity and resistance of NSCLC tumors to …

… in H3255 (table S3), whereas the other three cell lines did not contain EGFR mutations. We
also confirmed the presence of the L858R mutation in the primary tumor from which H3255 …

… Tumor mutation burden (TMB) is a biomarker of response to immune checkpoint blockade
(ICB). The impact of TMB on outcomes with targeted therapies has not been explored. …

… for EGFR Exon 19 deletion and EGFR L858R mutation. Results in plasma DNA samples
were compared with EGFR mutation status obtained in tumor DNA (18/31 EGFR mutant). The …